Transcriptional, functional, and mechanistic comparisons of stem cell-derived hepatocytes, HepaRG cells, and three-dimensional human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury

Drug Metabolism and Disposition

Volumn 45, Issue 4, 2017, Pages 419-429

  Bell, Catherine C ^a   Lauschke, Volker M ^a   Vorrink, Sabine U ^a   Palmgren, Henrik ^b   Duffin, Rodger ^c   Andersson, Tommy B ^a,b   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c CXR Biosciences Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARCINOGENESIS; CELL DIVISION; CELL FUNCTION; CHOLESTASIS; CONTROLLED STUDY; ENDOCYTOSIS; FATTY LIVER; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HEPARG CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LONG TERM EXPOSURE; MALE; MIDDLE AGED; PHENOTYPIC VARIATION; PLURIPOTENT STEM CELL; SPHEROID CELL; STEM CELL DERIVED HEPATOCYTE; THREE DIMENSIONAL HUMAN HEPATOCYTE SPHEROID; TOXIC HEPATITIS; TOXICOGENETICS; TRANSCRIPTOMICS; UPREGULATION; XENOBIOTIC METABOLISM; YOUNG ADULT; BIOLOGICAL MODEL; CELL CULTURE TECHNIQUE; COMPARATIVE STUDY; DRUG EFFECTS; ECONOMICS; GENE EXPRESSION PROFILING; IC50; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MULTICELLULAR SPHEROID; PROCEDURES;

XENOBIOTIC AGENT;

CELL CULTURE TECHNIQUES; CHEMICAL AND DRUG INDUCED LIVER INJURY; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; SPHEROIDS, CELLULAR; XENOBIOTICS;

EID: 85016014618     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.116.074369     Document Type: Article

References (87)

1. Anderson N and Borlak J (2006) Drug-induced phospholipidosis. FEBS Lett 580:5533-5540.
2. Anthérieu S, Rogue A, Fromenty B, Guillouzo A, and Robin MA (2011) Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 53:1895-1905.
3. Ayd FJ, Jr (1956) The dermatologic and systemic manifestations of chlorpromazine hypersensitivity; their clinical significance and management. J Nerv Ment Dis 124:84-87.
4. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, and Leape LL; Adverse Drug Events Prevention Study Group (1997) The costs of adverse drug events in hospitalized patients. JAMA 277:307-311.
5. Bell CC, Hendriks DFG, Moro SML, Ellis E, Walsh J, Renblom A, Fredriksson Puigvert L, Dankers ACA, Jacobs F, Snoeys J, et al. (2016) Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep 6: 25187.
6. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, and Olafsson S (2013) Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144:1419-1425.
7. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, and Ryan SI (1991) Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 325:87-91.
8. Chapman KL, Holzgrefe H, Black LE, Brown M, Chellman G, Copeman C, Couch J, Creton S, Gehen S, Hoberman A, et al. (2013) Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation. Regul Toxicol Pharmacol 66:88-103.
9. Chen HL, Liu YJ, Chen HL, Wu SH, Ni YH, Ho MC, Lai HS, Hsu WM, Hsu HY, Tseng HC, et al. (2008) Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr Res 63:667-673.
10. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, and Burke JP (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277: 301-306.
11. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, and Pangalos MN (2014) Lessons learned from the fate of Astra Zeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13:419-431.
12. Elaut G, Henkens T, Papeleu P, Snykers S, Vinken M, Vanhaecke T, and Rogiers V (2006) Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 7:629-660.
13. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, and Ahr HJ (2004) Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol Sci 77:19-34.
14. Fey SJ and Wrzesinski K (2012) Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicol Sci 127:403-411.
15. Fromenty B, Fisch C, Berson A, Letteron P, Larrey D, and Pessayre D (1990) Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 255:1377-1384.
16. Fulgencio JP, Kohl C, Girard J, and Pégorier JP (1996) Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45: 1556-1562.
17. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, and Gasser R (2001) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83-98.
18. García Rodríguez LA, Ruigómez A, and Jick H (1997) A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy 17:721-728.
19. Geba GP, Weaver AL, Polis AB, Dixon ME, and Schnitzer TJ; Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group (2002) Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 287:64-71.
20. Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, and Atienzar FA (2012) Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 28:69-87.
21. Gómez-Lechón MJ, Tolosa L, Conde I, and Donato MT (2014) Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol 10:1553-1568.
22. Gunness P, Mueller D, Shevchenko V, Heinzle E, Ingelman-Sundberg M, and Noor F (2013) 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol Sci 133: 67-78.
23. Hakkola J, Raunio H, Purkunen R, Saarikoski S, Vähäkangas K, Pelkonen O, Edwards RJ, Boobis AR, and Pasanen M (2001) Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 80:193-201.
24. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, and Nakamura Y (2004) SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6:731-740.
25. Hassan AM, Sheashaa HA, Abdel Fatah MF, Ibrahim AZ, and Gaber OA (2006) Does aflatoxin as an environmental mycotoxin adversely affect the renal and hepatic functions of Egyptian lactating mothers and their infants? A preliminary report. Int Urol Nephrol 38:339-342.
26. Heslop JA, Rowe C, Walsh J, Sison-Young R, Jenkins R, Kamalian L, Kia R, Hay D, Jones RP, Malik HZ, et al. (2017) Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. Arch Toxicol 91:439-452.
27. Horikawa M, Kato Y, Tyson CA, and Sugiyama Y (2003) Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet 18:16-22.
28. Johnson WW and Guengerich FP (1997) Reaction of aflatoxin B1 exo-8,9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis. Proc Natl Acad Sci USA 94: 6121-6125.
29. Jossé R, Dumont J, Fautrel A, Robin MA, and Guillouzo A (2012) Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicol Appl Pharmacol 258:176-187.
30. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499.
31. Kenne K, Skanberg I, Glinghammar B, Berson A, Pessayre D, Flinois JP, Beaune P, Edebert I, Pohl CD, Carlsson S, et al. (2008) Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 22:730-746.
32. Kennedy JA, Unger SA, and Horowitz JD (1996) Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52:273-280.
33. Kia R, Sison RLC, Heslop J, Kitteringham NR, Hanley N, Mills JS, Park BK, and Goldring CEP (2013) Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol 75:885-896.
34. Klein S, Mueller D, Schevchenko V, and Noor F (2014) Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study. J Appl Toxicol 34:1078-1086.
35. Krenkel O, Mossanen JC, and Tacke F (2014) Immune mechanisms in acetaminophen-induced acute liver failure. Hepatobiliary Surg Nutr 3:331-343.
36. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, and Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287: 2215-2220.
37. Lauschke VM, Hendriks DFG, Bell CC, Andersson TB, and Ingelman-Sundberg M (2016a) Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chem Res Toxicol 29:1936-1955.
38. Lauschke VM and Ingelman-Sundberg M (2016) The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci 17:1714-1727.
39. Lauschke VM, Mkrtchian S, and Ingelman-Sundberg M (2016b) The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration. Biochem Biophys Res Commun DOI: 10.1016/j.bbrc.2016.10.084 [published ahead of print].
40. Lauschke VM, Vorrink SU, Moro SM, Rezayee F, Nordling Å, Hendriks DF, Bell CC, Sison-Young R, Park BK, Goldring CE, et al. (2016c) Massive rearrangements of cellular microRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology 64:1743-1756.
41. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
42. Li Y, Wan DF, Su JJ, Cao J, Ou C, Qiu XK, Ban KC, Yang C, Qin LL, Luo D, et al. (2004) Differential expression of genes during aflatoxin B(1)-induced hepatocarcinogenesis in tree shrews. World J Gastroenterol 10:497-504.
43. Lim PLK, Liu J, Go ML, and Boelsterli UA (2008) The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol Sci 101:341-349.
44. Loi CM, Alvey CW, Vassos AB, Randinitis EJ, Sedman AJ, and Koup JR (1999) Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J Clin Pharmacol 39:920-926.
45. Macé K, Aguilar F, Wang JS, Vautravers P, Gómez-Lechón M, Gonzalez FJ, Groopman J, Harris CC, and Pfeifer AM (1997) Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18:1291-1297.
46. Masubuchi Y (2006) Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 21:347-356.
47. McCarthy TC, Pollak PT, Hanniman EA, and Sinal CJ (2004) Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. J Pharmacol Exp Ther 311: 864-873.
48. Mueller D, Krämer L, Hoffmann E, Klein S, and Noor F (2014) 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. Toxicol In Vitro 28: 104-112.
49. Nadanaciva S, Bernal A, Aggeler R, Capaldi R, and Will Y (2007) Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro 21:902-911.
50. Natarajan K, Xie Y, Baer MR, and Ross DD (2012) Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 83:1084-1103.
51. Neve EPA, Köfeler H, Hendriks DFG, Nordling Å, Gogvadze V, Mkrtchian S, Näslund E, and Ingelman-Sundberg M (2015) Expression and function of mARC: roles in lipogenesis and metabolic activation of ximelagatran. PLoS One 10:e0138487.
52. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, and Schaeffeler E (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227-1240.
53. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SHB, McCashland TM, Shakil AO, Hay JE, Hynan L, et al.; U.S. Acute Liver Failure Study Group (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947-954.
54. Park BK, Boobis A, Clarke S, Goldring CEP, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, et al. (2011) Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 10:292-306.
55. Parmentier C, Truisi GL, Moenks K, Stanzel S, Lukas A, Kopp-Schneider A, Alexandre E, Hewitt PG, Mueller SO, and Richert L (2013) Transcriptomic hepatotoxicity signature of chlorpromazine after short-and long-term exposure in primary human sandwich cultures. Drug Metab Dispos 41:1835-1842.
56. Pradip A, Steel D, Jacobsson S, Holmgren G, Ingelman-Sundberg M, Sartipy P, Björquist P, Johansson I, and Edsbagge J (2016) High content analysis of human pluripotent stem cell derived hepatocytes reveals drug induced steatosis and phospholipidosis. Stem Cells Int 2016: 2475631.
57. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O'Dushlaine C, Chambert K, Bergen SE, Kähler A, et al. (2014) A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506:185-190.
58. Raijmakers MT, Steegers EA, and Peters WH (2001) Glutathione S-transferases and thiol concentrations in embryonic and early fetal tissues. Hum Reprod 16:2445-2450.
59. Ramaiahgari SC, den Braver MW, Herpers B, Terpstra V, Commandeur JNM, van de Water B, and Price LS (2014) A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch Toxicol 88: 1083-1095.
60. Regenthal R, Krueger M, Koeppel C, and Preiss R (1999) Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 15:529-544.
61. Ros E, Small DM, and Carey MC (1979) Effects of chlorpromazine hydrochloride on bile salt synthesis, bile formation and biliary lipid secretion in the rhesus monkey: a model for chlorpromazine-induced cholestasis. Eur J Clin Invest 9:29-41.
62. Russo MW, Galanko JA, Shrestha R, Fried MW, and Watkins P (2004) Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 10: 1018-1023.
63. Sakai Y, Yamagami S, and Nakazawa K (2010) Comparative analysis of gene expression in rat liver tissue and monolayer-and spheroid-cultured hepatocytes. Cells Tissues Organs 191: 281-288.
64. Schutte M, Fox B, Baradez M-O, Devonshire A, Minguez J, Bokhari M, Przyborski S, and Marshall D (2011) Rat primary hepatocytes show enhanced performance and sensitivity to acetaminophen during three-dimensional culture on a polystyrene scaffold designed for routine use. Assay Drug Dev Technol 9:475-486.
65. Schützer KM, Wall U, Lönnerstedt C, Ohlsson L, Teng R, Sarich TC, and Eriksson UG (2004) Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. Curr Med Res Opin 20:325-331.
66. Selim K and Kaplowitz N (1999) Hepatotoxicity of psychotropic drugs. Hepatology 29:1347-1351.
67. Sevilla-Tirado FJ, González-Vallejo EB, Leary AC, Breedt HJ, Hyde VJ, and Fernández-Hernando N (2003) Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. Methods Find Exp Clin Pharmacol 25: 531-535.
68. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, and Hillon P (2002) Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451-455.
69. Sison-Young RL, Lauschke VM, Johann E, Alexandre E, Anthérieu S, Aerts H, Gerets HHJ, Labbe G, Hoët D, Dorau M, et al. (2016) A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch Toxicol DOI: 10.1007/s00204-016-1745-4 [published online ahead of print].
70. Soyama A, Hanioka N, Saito Y, Murayama N, Ando M, Ozawa S, and Sawada J (2002) Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8∗3 and CYP2C8 P404A. Pharmacol Toxicol 91:174-178.
71. Spaniol M, Bracher R, Ha HR, Follath F, and Krähenbühl S (2001) Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol 35:628-636.
72. Takara K, Sakaeda T, and Okumura K (2006) An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12:273-286.
73. Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K, Sakurai F, Tachibana M, Kanda K, Hayakawa T, Furue MK, et al. (2013) 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 34:1781-1789.
74. Tasnim F, Toh YC, Qu Y, Li H, Phan D, Narmada BC, Ananthanarayanan A, Mittal N, Meng RQ, and Yu H (2016) Functionally enhanced human stem cell derived hepatocytes in galactosylated cellulosic sponges for hepatotoxicity testing. Mol Pharm 13:1947-1957.
75. Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, Hart TK, Thomas HC, and Schwartz LW (2002) Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 69:131-138.
76. Tostões RM, Leite SB, Serra M, Jensen J, Björquist P, Carrondo MJT, Brito C, and Alves PM (2012) Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 55:1227-1236.
77. Trivier JM, Libersa C, Belloc C, and Lhermitte M (1993) Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report). Life Sci 52: PL91-PL96.
78. Vale JA and Proudfoot AT (1995) Paracetamol (acetaminophen) poisoning. Lancet 346: 547-552.
79. Wang J, Duncan D, Shi Z, and Zhang B (2013) WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res 41:W77-W83.
80. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, and Harris SC (2006) Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 296:87-93.
81. Watson RG, Olomu A, Clements D, Waring RH, Mitchell S, and Elias E (1988) A proposed mechanism for chlorpromazine jaundice-defective hepatic sulphoxidation combined with rapid hydroxylation. J Hepatol 7:72-78.
82. Weiske J, Albring KF, and Huber O (2007) The tumor suppressor Fhit acts as a repressor of betacatenin transcriptional activity. Proc Natl Acad Sci USA 104:20344-20349.
83. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, and Aggarwal D (2004) Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 80:1106-1122.
84. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, and de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:97-105.
85. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, and Chiba K (2000) Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 67:175-184.
86. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, et al. (2001) Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33:633-646.
87. Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, and Trauner M (2007) Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 27: 920-929.